Enumeral to Participate in Immuno-Oncology Panel at the Cantor Fitzgerald Inaugural Healthcare Conference

CAMBRIDGE, Mass.--()--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of Enumeral, will participate in a panel discussion, titled “Continued Opportunities in Immuno-Oncology; Exploring Next-Generation Checkpoint Inhibition,” at the Cantor Fitzgerald Inaugural Healthcare Conference, to be held at Le Parker Meridien Hotel in New York City on Wednesday, July 8, 2015 at 11:15 AM ET.

“Continued Opportunities in Immuno-Oncology; Exploring Next-Generation Checkpoint Inhibition”

About Enumeral

Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, Tim3, Lag-3, OX40, and VISTA. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.

Contacts

Burns McClellan, Inc., on behalf of Enumeral Biomedical Holdings
Investors
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Justin Jackson, 212-213-0006, ext. 327
jjackson@burnsmc.com

Recent Stories

RSS feed for Enumeral Biomedical Holdings, Inc.

Enumeral Biomedical Holdings, Inc.